Biotech firm ImmunoCellular Therapeutics (OTC:IMUC) said Tuesday it plans to make a presentation on immunogenic epitopes at a cancer research meeting in Chicago.
The presentation is scheduled to take place at the Annual Meeting of
the American Association for Cancer Research from March 31 to April 4,
2012, at the McCormick Place in Chicago.
ImmunoCellular will deliver its lecture on Sunday April 1, 2012 from 1 p.m. to 5 p.m. central standard time.
The development stage company develops therapies to treat cancer
using the immune system. Its product portfolio includes cellular
immunotherapies targeting cancer stem cell antigens and monoclonal
anti-bodies to diagnose and treat various cancers.
ImmunoCellular said its presentation will be on the identification
and characterization of immunogenic epitopes from CD133 and their
potential to immunologically target cancer stem cells.
CD133 is a marker that identifies cancer stem cells on many solid
tumors and its expression has been correlated with shortened survival.
Potential Cytotoxic T Lymphocytes epitopes were identified by
computer algorithms to predict binding to HLA-A2 tissue type on white
Studies with human cells in vitro demonstrated immunogenicity of two
lead peptides and in vivo studies in mice confirmed the safety and
immunogenicity of these peptides as a potential vaccine to target CD133
cancer stem cells, the company said.
The company said it plans to incorporate these peptides into its
second product, ICT-121, for recurrent glioblastoma as the initial
indication, followed by additional solid tumours.
To evaluate the potential for autoimmunity, mouse homolog peptides of
the lead epitopes that were shown to have high affinity binding to
human HLA-A2 were used to immunize HLA-A2 transgenic mice.
Mice were immunized three times at three week intervals and spleens
were harvested and stimulated in vitro for one week, with peptide pulsed
antigen presentation cells.
Interferon gamma tests showed immune responses to the two lead peptides in 35 and 40 percent of mice.
of mice with immune responses, including heart, lung, kidneys and eyes,
were found to be negative for lymphocytic infiltrations, supporting a
lack of autoimmunity related to the immune response to these peptides,
the company said.
Together, these studies support the safety and immunogenicity of
these peptides as a potential vaccine to target CD133 cancer stem cells,
headquartered is a Los Angeles, is a clinical-stage company that is
developing immune-based therapies for the treatment of brain and other
Recently, it began a phase II trial for its lead product candidate,
ICT-107, a dendritic cell-based vaccine targeting multiple tumour
associated antigens for glioblastoma, an aggressive type of brain